Indoco Remedies gets EU GMP certification from German Health Authority for Goa facility (Plant III)
Mumbai: Indoco Remedies received EU GMP certification from the Competent Health Authority of Germany for its manufacturing site situated at L-32/33/34 Verna Industrial Estate, Goa.
The European Agency conducted an inspection at Indoco’s manufacturing facility for solid oral dosage form in Goa (Plant -III) from April 20-25, 2023.
The EU GMP certification issued by the German Health Authority (LAGeSo) confirms that the site complies with the Good Manufacturing Practice requirements as referred to in the EC Directive. The EU certification will support supplies of drug products registered in Europe and other regions from this manufacturing site.
Commenting on the development, Ms. Aditi Panandikar, Managing Director – Indoco Remedies Ltd. said, “The EU GMP certification for our site in Goa (Plant - III) complements our unswerving efforts to supply quality and affordable medicines in Europe and other geographies. We remain fully committed to adhering to cGMP standards and ensuring the delivery of quality products to our valued customers and patients worldwide.”
Medical Dialogues team had earlier reported that the Company's Baddi facility had also received EU GMP certification from the Competent Health Authority of Germany.
Read also: Indoco Remedies Baddi facility bags EU GMP certification from Health Authority of Germany
Indoco is a fully integrated, research-oriented pharmaceutical company with presence in 55 countries. The Company’s turnover is US$ 200 million with a human capital of 6000 employees, including over 300 skilled scientists and Field Staff.
The Company has 9 manufacturing facilities, 6 for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 109 million prescriptions annually from over 3,00,000 doctors belonging to various specialties.
Indoco has 9 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infective, Stomatologicals, Ophthalmic, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management, Gyneacology etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Sensoform, Sensodent-KF, Cloben-G, Glychek, Kidodent, Carmicide, Rexidin, MCBM 69, Methycal, Homide, Cal-Aid, etc. On the international front, Indoco has tie-ups with large generic companies across the globe.
